“We, and the pharmaceutical industry generally, depend on China-based partners for integral chemical synthesis, reagents, starting materials, and ingredients,” Lilly said in a recent filing with the US Securities and Exchange Commission. Finding alternative suppliers if necessary due to geopolitical developments may not be feasible and “would cause disruptions to patients and detrimentally impact our business,” the company said.
礼来在最近提交给美国证券交易委员会（SEC）的一份文件中表示：“我们，以及整个制药行业，在整体化学合成、试剂、起始原料和成分方面，依赖中国的合作伙伴。”该公司表示，由于地缘政治的发展，在必要时寻找替代供应商可能不可行，并且“将对患者造成干扰，并对我们的业务造成不利影响”。#原料药# #CXO# $药明康德(SH603259)$ $康龙化成(SZ300759)$